Genomic Testing

FoundationOne®

Our flagship assay for solid tumor cancers including but not limited to: Non-Small Cell Lung Cancer (NSCLC), Colorectal, Breast, Ovarian, and Melanoma
  • Cancer Type
    Solid Tumor
  • Biopsy Type
    FFPE
  • Results Expected
    2 Weeks

What is FoundationOne?

FoundationOne is a validated comprehensive genomic profile (CGP) for solid tumors. The test is designed to provide physicians with clinically actionable information to guide treatment decisions for patients based on the genomic profile of their disease. Test results provide information about clinically significant alterations, potential targeted therapies, available clinical trials, and quantitative markers of response for immunotherapy.

FoundationOne is validated to detect all classes of genomic alterations in more than 300 cancer-related genes, including select introns from more than 25 genes often rearranged or altered in solid tumors.

Overview

FoundationOne

  • >300

    genes interrogated

  • >25

    select introns profiled

  • >99%

    specificity (PPV)*

  1. A single test that detects all four classes of genomic alterations for solid tumors
  2. Results include microsatellite instability (MSI) and tumor mutational burden (TMB) measurements, which may help predict response to immunotherapy
  3. Typical median depth of coverage of >500x for sensitive and specific detection of alterations at low frequency**

Learn about the predictive power of TMB for immunotherapy.

Publications

FoundationOne has been validated to detect all four classes of genomic alterations.

Validation Study in Nature Biotechnology

Published Clinical Study

Individualized Molecular Analyses Guide Efforts (IMAGE)

A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer.

Clinical Cancer Research (2017)

View the Published Paper

Published Clinical Study

Clinical utility and treatment outcome of CGP in high-grade glioma

Genomic research of high-grade glioma (HGG) has revealed complex biology with potential for therapeutic impact.

Journal of Neuro-Oncology (2016)

View the Published Paper

Interested in learning more about how a Comprehensive Genomic Profiling test might help your patient? Our publications can help:

View all reports & validation

Order FoundationOne

We provide physicians with several options for ordering FoundationOne for patients including online, fax, and phone. Healthcare providers must first complete a test requisition form to start the process and can expect results within 2 weeks from the time a specimen is received.

A doctor looking at the camera

Questions?
We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact

Patients

FoundationOne is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationOne testing.

Patient Info Kit (PDF)

We have even more to offer.

Learn more about our other tests, FoundationACT®, FoundationFocus™ CDxBRCA, FoundationOne®Heme, or explore our insights partnerships.

* Specificity is the ability of the test to correctly identify individuals without the disease (true negative rate). PPV = Positive Predictive Value.

** Depth of Coverage is a measure of how many different DNA molecules are sequenced. Detecting alterations are wholly dependent on the number of unique different DNA molecules that are sequenced.